About the Company
We do not have any company description for Aptose Biosciences Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Aptose Biosciences Inc.
Aptose Reports Second Quarter 2025 Results
Net loss for the quarter ended June 30, 2025 decreased by $0.2 million to $7.0 million, as compared to $7.3 million for the comparable period in 2024. Net loss for the six months ended June 30, 2025 ...
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
Safety Review Committee endorses escalation to 160 mg TUS dosingCohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with ...
Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
Aptose Biosciences Inc. Announces Pricing of $8 ... - Markets Insider
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...
Aptose Biosciences Inc. Announces Reverse Share Split to ... - Nasdaq
Aptose Biosciences Inc. announced a plan to consolidate its outstanding common shares on a 1-for-30 basis, subject to regulatory approval, in an effort to comply with NASDAQ's minimum bid price ...
Aptose Biosciences Inc. Company & People | APS | Barron's
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small ...
APTOF - Aptose Biosciences Inc News | Morningstar
Aptose Biosciences Inc APTOF Stock PINX Rating as of Apr 4, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends ...
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com Source: Aptose Biosciences, Inc. 2024 GlobeNewswire, Inc.
Aptose Biosciences Inc. Announces Pricing of $8 Million Public ... - Nasdaq
--Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its ...
Similar Companies
Loading the latest forecasts...